influenza
viru
continu
threaten
public
health
high
morbid
mortal
rate
despit
effort
success
antivir
research
accord
world
health
organ
season
influenza
viru
epidem
result
infect
million
peopl
death
worldwid
recent
year
emerg
highli
aggress
viru
strain
reemphas
need
therapeut
strategi
overcom
pathogen
vaccin
antivir
agent
essenti
mitig
influenc
influenza
viru
due
frequent
variat
influenza
viru
antiinfluenza
agent
seem
effect
prevent
highli
contagi
infect
viru
treat
diseas
epidem
influenza
pandem
caus
influenza
viru
negativesens
singlestrand
member
orthomyxovirida
famili
rna
virus
influenza
viru
could
classifi
one
three
distinct
subtyp
influenza
influenza
b
influenza
c
depend
nucleoprotein
antigen
determin
matrix
protein
influenza
influenza
b
appear
caus
highli
infecti
diseas
influenza
c
seem
caus
signific
diseas
howev
pandem
outbreak
caus
influenza
virus
therefor
much
attent
paid
influenza
virus
structur
influenza
viru
contain
three
motif
figur
core
matrix
protein
viral
envelop
influenza
viru
made
protein
encod
eight
segment
negativestrand
rna
protein
includ
hemagglutinin
ha
neuraminidas
na
nucleoprotein
np
rna
polymeras
pa
matrix
protein
proton
channel
protein
nonstructur
protein
nuclear
export
protein
nep
addit
protein
exist
particular
strain
identifi
recent
pax
moreov
novel
protein
identifi
recent
depend
differ
subtyp
ha
na
influenza
virus
classifi
subtyp
life
cycl
influenza
viru
complex
biolog
process
divid
follow
step
figur
attach
virion
cell
surfac
receptor
bind
ii
endosom
intern
viru
cell
endocytosi
endocytosi
iii
uncoat
cytoplasm
transport
nuclear
import
viral
ribonucleoprotein
vrnp
iv
transcript
replic
viral
rna
v
nuclear
export
protein
synthesi
vi
viral
progeni
assembl
bud
releas
cell
membran
viral
protein
host
cellular
protein
involv
step
life
cycl
viru
infect
attract
target
combat
influenza
viru
infect
present
drug
function
influenza
na
inhibitor
ion
channel
protein
inhibitor
rnadepend
rna
polymeras
inhibitor
proteas
inhibitor
use
clinic
structur
current
avail
licens
antiinfluenza
drug
shown
figur
emerg
influenza
viru
mutat
acquir
resist
extrem
influenti
drive
develop
new
antiinfluenza
agent
possibl
futur
influenza
epidem
small
molecular
inhibitor
molecular
weight
less
power
tool
fight
influenza
viru
besid
small
molecular
inhibitor
peptid
entri
blockpeptid
ebpeptid
flupep
fp
peptid
ndfrskt
etc
protein
hepatocyt
growth
factor
activ
inhibitor
ulinastatin
fludas
monoclon
antibodi
nanoparticl
type
antivir
drug
effect
influenza
viru
infect
agent
scope
articl
accord
target
antivir
agent
research
antiinfluenza
viru
agent
current
categor
two
field
agent
target
function
protein
viru
agent
target
potenti
site
host
cell
antivir
compound
design
discov
interrupt
attach
entri
cours
viru
name
entri
inhibitor
extract
natur
produc
tradit
chines
medicin
tcm
licoric
triterpenoid
deriv
show
antivir
activ
glycyrrhiz
acid
name
glycyrrhizin
glycyrrhetin
acid
prove
effect
interrupt
attach
entri
cours
influenza
viru
figur
glycyrrhizin
exhibit
broad
spectrum
inhibitori
activ
show
potent
inhibitori
activ
replic
etc
saponin
uralsaponin
figur
show
antiinfluenza
activ
recent
studi
uralsaponin
exhibit
inhibitori
activ
influenza
viru
mdck
cell
line
valu
neg
charg
sulphat
polysaccharid
dextran
sulphat
ds
figur
inhibit
attach
entri
cours
well
hadepend
nadepend
fusion
cours
strictli
speak
ds
small
molecular
silymarin
figur
extract
milk
thistl
seed
show
activ
influenza
main
compon
silibinin
deriv
also
regul
autophagi
cours
multitarget
natur
product
curcumin
also
inhibit
viru
entri
cours
ha
activ
approxim
inhibit
influenza
viru
plaqu
reduct
assay
lysosomotrop
agent
concanamycin
bafilomycin
chloroquin
etc
exhibit
antiinfluenza
activ
depend
ph
valu
intracellular
environ
ha
encod
vrna
compos
three
ident
structur
subunit
subunit
two
import
function
linkag
intern
trigger
first
ha
provid
link
viru
surfac
target
host
cell
second
ha
trigger
intern
viru
fusion
viral
envelop
endosom
membran
host
ha
na
recogn
nacetylneuramin
acid
also
call
sialic
acid
typic
termin
unit
glycoconjug
attach
membran
cell
upper
respiratori
tract
lung
facil
function
ha
form
via
proteolyt
cleavag
precursor
protein
either
inhibitor
ha
classifi
two
differ
subtyp
first
type
inhibitor
block
associ
neuramin
acid
neu
receptor
surfac
target
host
cell
second
type
inhibitor
stachyflin
interrupt
mediat
fusion
process
figur
second
type
inhibitor
inhibit
conform
transit
induc
lower
ph
valu
extract
cotton
plant
natur
phenol
aldehyd
name
gossypol
figur
found
effect
pneumonia
caus
influenza
viru
studi
found
natur
product
deriv
rutin
quercetin
xylopin
theaflavin
ha
inhibitor
interact
ha
figur
contain
salicylamid
scaffold
identifi
specif
influenza
viru
valu
mm
multicycl
replic
assay
viru
found
inhibit
virus
though
inact
viru
earli
stage
infect
studi
indic
block
hamedi
fusion
process
stachyflin
figur
ha
inhibitor
similar
activ
influenza
virus
experi
suggest
stachyflin
block
hamedi
cell
fusion
process
inhibit
conform
transit
ha
protein
interest
trival
glycopeptid
mimet
compound
figur
display
inhibitori
activ
ha
avian
influenza
inhibitori
constant
ki
compound
small
molecular
compound
simpli
subdivid
peptid
either
followup
work
carri
zhao
et
al
found
seri
podocarp
acid
deriv
compound
figur
exhibit
potent
activ
nm
celllin
adapt
influenza
viru
apuerto
oseltamivir
amantadin
resist
strain
infect
mdck
madindarbi
canin
kidney
cell
natur
product
pentacycl
triterpenoid
compound
figur
exhibit
inhibitori
influenza
virus
compar
even
potent
oseltamivir
compound
effect
strain
amantadin
ribavirin
resist
aliaoningzhenx
strain
oseltamivirresist
even
influenza
valu
mdck
cell
base
cytopath
effect
reduct
assay
cpe
assay
obtain
marinederiv
fungu
eurotium
rubrum
class
novel
prenyl
indol
diketopiperazin
alkaloid
display
potent
inhibit
viru
includ
oseltamivir
amantadineresist
clinic
isol
indol
alkaloid
neoechinulin
b
disrupt
interact
viru
host
cell
bing
influenza
envelop
ha
valus
neoechinulin
b
respect
mdck
cell
base
cpe
assay
thiazolid
nitazoxanid
figur
power
broadspectrum
antivir
drug
block
matur
viral
ha
made
activ
influenza
virus
valus
nitazoxanid
influenza
oseltamivirresist
amantadineresist
respect
mdck
cellbas
cpe
assay
na
also
call
sialidas
viral
enzym
made
four
ident
subunit
anchor
membran
viru
na
play
key
role
spread
viru
termin
neuramin
acid
residu
glycoprotein
newli
form
virion
progeni
form
glycosid
linkag
neuramin
acid
receptor
hostcel
surfac
glycosid
linkag
cleav
na
therebi
assist
releas
virion
progeni
infect
cell
therefor
na
attract
target
antiinfluenza
research
inhibitor
na
contain
neu
core
attract
much
attent
meindl
et
al
synthes
fana
dana
analogu
sialic
acid
figur
howev
studi
indic
dana
limit
activ
fail
clinic
treatment
influenza
von
itzstein
colleagu
modifi
structur
dana
synthes
novel
na
inhibitor
zanamivir
figur
zanamivir
effect
influenza
viru
valu
nm
nm
respect
mdck
cellbas
plaqu
reduct
assay
although
oral
bioavail
zanamivir
low
fda
approv
first
na
inhibitor
agent
formul
oral
inhal
base
structur
zanamivir
structur
zanamivir
influenzaviru
na
subtyp
kim
et
al
synthes
oseltamivir
figur
enhanc
oral
bioavail
fda
also
approv
oseltamivir
popular
na
inhibitor
clinic
present
activ
oseltamivir
carboxyl
repres
na
rang
nm
nm
neuraminidas
enzym
assay
importantli
zanamivir
oseltamivir
effect
amantadan
resist
strain
peramivir
laninamivir
also
use
na
inhibitor
current
licens
asian
countri
figur
peramivir
administ
intraven
poor
bioavail
laninamivir
show
potent
na
inhibitori
activ
strain
virus
strain
strain
b
virus
valus
rang
nm
nm
nm
respect
enzymat
assay
laninamivir
also
formul
oral
inhal
longterm
na
inhibitor
appear
effect
patient
oseltamivir
resist
suggest
treatment
usag
laninamivir
japan
benefici
patient
confer
resist
oseltamivir
recent
progress
research
na
inhibitor
mainli
focus
structur
modificationoptim
zanamivir
oseltamivir
similar
neu
analogu
compound
figur
develop
irrevers
inhibitor
attract
strategi
overcom
drug
resist
design
synthes
kim
et
al
compound
repres
compound
figur
could
form
transient
coval
intermedi
locat
catalyt
domain
na
therebi
gain
potent
broadspectrum
inhibitori
activ
drugresist
strain
furthermor
compound
exhibit
equival
better
drug
efficaci
anim
experi
remark
dimer
tether
na
inhibitor
develop
tucker
cowork
prospect
clinic
realiz
antiinfluenza
agent
dimer
zanamivir
conjug
synthes
prove
highli
potent
na
inhibitor
figur
dimer
compound
show
broadspectrum
activ
fold
potent
zanamivir
aim
find
novel
potent
na
inhibitor
benzoic
acid
deriv
figur
develop
recent
studi
howev
plane
aromat
ring
may
limit
orient
substitu
group
result
poor
activ
benzoic
acid
deriv
pyrrolidin
deriv
also
effect
influenza
viru
figur
wang
et
al
found
compound
show
antiinfluenza
activ
na
atokyo
na
bmemphi
na
inhibit
assay
compound
compound
show
antiinfluenza
activ
influenza
influenza
b
respect
compound
analogu
l
prolin
show
inhibitori
activ
na
influenza
viru
natur
product
also
found
possess
antiinfluenza
activ
past
year
figur
ginkgetinsial
acid
conjug
compound
significantli
improv
surviv
rate
mice
infect
influenza
viru
flavanon
flavonoid
figur
also
show
potent
na
inhibit
rang
na
na
inhibit
assay
isoscutellarein
compound
deriv
also
activ
cellular
assay
influenza
mdck
cellbas
cpe
assay
anim
model
novel
highli
potent
oral
drug
candid
figur
exhibit
subnanomolar
activ
influenza
viru
na
vitro
nm
nm
na
na
enzym
base
assay
respect
nsubstitut
oseltamivir
analogu
compound
figur
display
enhanc
inhibit
na
oseltamivirresist
wildtyp
strain
jinhyo
kim
et
al
synthes
seri
coval
na
inhibitor
repres
compound
figur
introduc
strong
electroneg
fluorin
atom
corer
zanamivir
oseltamivir
compound
show
excel
antivir
activ
vitro
compound
showd
valu
nm
nm
agaisnt
plaqu
size
reduct
assay
superior
zanamivir
nm
nm
respect
compound
also
showd
compar
inhibit
level
anim
model
compar
zanamivir
rnadepend
rna
polymeras
rdrp
influenza
viru
highli
conserv
among
strain
subtyp
evolut
unlik
mammal
rdrp
influenza
viru
exhibit
activ
replicas
endonucleas
earli
stage
infect
rdrp
synthes
mrna
use
vrna
templat
advanc
stage
infect
conform
rdrp
chang
rdrp
becom
respons
catalyt
synthesi
crna
vrna
rdrp
also
name
compos
three
subunit
pa
rdrp
play
critic
role
life
cycl
viru
therefor
becom
promis
target
develop
antiinfluenza
drug
recent
year
base
mechan
interact
berween
inhibitor
polymeras
rdrp
inhibitor
easili
subdivid
follow
four
subtyp
rdrp
disrupt
compound
ii
cabbind
inhibitor
iii
pa
endonucleas
inhibitor
iv
nucleosid
analogu
like
inhibitor
rdrp
disrupt
compound
attract
strategi
develop
rdrp
inhibitor
appear
interrupt
subunit
interact
assembl
cours
subunit
function
polymeras
complex
strategi
prove
effect
recent
studi
figur
show
structur
typic
rdrp
disrupt
inhibitor
compound
figur
rdrp
disrupt
compound
also
name
prpoteinprotein
interact
inhibitor
ppi
inhibitor
interferenceor
inhibiton
proteinprotein
interact
assembl
cours
cabbind
inhibitor
capbind
activ
resid
subunit
discov
year
ago
bind
mode
influenza
b
reveal
sinc
xray
structur
capbind
domain
report
drug
target
valid
clinic
candid
figur
azaindol
base
inhibitor
abl
occupi
bind
pocket
influeza
demonstr
xray
structur
display
potent
antivir
activ
wide
rang
influenza
viru
strain
cellular
assay
nanomolar
rang
includ
amantadin
nairesist
strain
figur
also
capbind
inhibitor
report
recent
roch
et
al
two
compound
inhibit
transcript
process
enzymat
assay
inhibit
viru
replic
process
cell
experi
rang
pa
endonucleas
inhibitor
anoth
promis
target
polymeras
may
conserv
residu
insid
catalyt
site
ntermin
domain
pa
strageti
also
valid
sinc
introduct
structur
undisclos
pa
inhibitor
clinic
trial
challeng
strategi
achiev
inhibitor
consist
metalchel
scaffold
bind
dival
metal
ion
occupi
panter
catalyt
site
mani
inhibitor
type
report
far
inhibitor
common
possess
chelat
motif
inhibitor
includ
egcg
aliphat
analogu
egcg
analogu
also
show
inhibitori
activ
neuraminidas
nhydroxam
acid
nhydroxyimid
flutimid
aromat
analogu
tetram
acid
deriv
polyphenol
catechin
phenethylphenylphthalimid
analogu
macrocycl
bisbibenzyl
pyrimidinol
fulleren
hydroxi
quinolinon
hydroxypyridinon
nm
enzym
assay
compound
hydroxypyridazinon
trihydroxyphenylbear
compound
compound
hydroxypyrimidinon
acid
bioisoster
compound
thiosemicarbazon
bisdihydroxyindolecarboxamid
pyridopiperazinedion
miscellan
compound
howev
quit
number
compound
show
cell
experi
like
connect
poor
cellular
uptak
andor
insuffici
antivir
activ
select
structur
repres
inhibitor
shown
figur
nucleosid
nucleobas
analogu
inhibitor
subtyp
rdrp
inhibitor
like
promis
antiinfluenza
drug
develop
follow
advanc
low
cytotox
high
resist
barrier
broad
coverag
divers
rna
virus
ribavirin
figur
favipiravir
also
name
figur
rdrp
inhibitor
nucleosid
fragment
ribavirin
approv
broadspectrum
antivir
drug
year
favipiravir
advanc
phase
ii
clinic
trial
usa
phase
iii
clinic
trial
japan
ribavirin
influenc
dnarna
synthesi
host
cell
combin
sever
differ
mechan
research
reveal
ribavirin
analogu
lethal
mutagen
influenza
viru
nucleobas
mimet
favipiravir
analogu
show
effect
strain
resist
na
inhibitor
ion
channel
protein
inhibitor
nucleosid
analogu
analogu
carbanucleosid
analogu
purin
nucleosid
analogu
etc
report
posess
antiinfluenza
activ
influenza
b
virus
inhibit
polymeras
complex
nonoblig
chain
termin
pyrimidin
analogu
seem
potent
variou
strain
influenza
andor
b
vitro
vivo
although
nucleosid
analogu
show
strong
inhibitori
activ
clinic
applic
limit
therapeut
window
narrow
np
account
total
protein
viru
structur
protein
form
viru
ribonucleoprotein
vrnp
np
multipl
function
viru
involv
replic
format
specif
host
activ
recent
research
result
discoveri
potenti
target
inhibitor
np
studi
carri
ye
cowork
indic
tail
loopbind
pocket
influenza
viru
np
could
potenti
site
antivir
develop
kao
et
al
found
small
molecular
nucleozin
ncz
figur
may
inhibit
infect
caus
strain
initi
aggreg
process
np
block
nuclear
accumul
showd
mdck
cellbas
plaqu
reduct
assay
respect
work
also
prove
viral
np
potenti
target
develop
antiinfluenza
drug
ke
ding
et
al
replac
isoxazol
ring
nucleozin
triazol
obtain
compound
figur
show
enhanc
activ
replic
variou
influenza
viru
strain
rang
mdck
cellbas
antiinfluenza
assay
furthermor
compound
also
effect
strain
resist
amantadin
oseltamivir
small
molecul
cycloheximid
chx
figur
naproxen
figur
found
effect
function
polymer
np
monom
furthermor
licens
drug
name
ingavirin
approv
russia
figur
interact
np
directli
interrupt
transport
newli
synthes
np
nucleu
ion
channel
protein
transmembran
protein
possess
activ
typic
ion
channel
influenza
b
lack
ion
channel
protein
protein
function
ion
channel
protein
assembl
viru
protein
play
import
role
incorpor
viral
ribonucleoprotein
vrnp
complex
viru
assembl
process
although
inhibitor
amantadin
rimantadin
firstli
approv
recommend
use
clinic
drug
resist
limit
clinic
use
strain
viru
b
resist
amantadan
resist
zanamivir
oseltamivir
low
furthermor
neurotox
effect
confus
disorient
anxieti
jitteri
etc
caus
amantadin
usual
common
drug
use
week
sinc
structur
channel
protein
determin
develop
potent
drug
influenza
viru
solv
drugresist
problem
becom
promis
inhibitor
classifi
two
group
base
structur
inhibitor
first
group
includ
amantadin
rimantadin
analogu
figur
compound
amantadin
compound
show
activ
influenza
viru
mdck
cellbas
cpe
assay
respect
second
group
nonadamantan
deriv
promis
drug
polyamin
effect
influenza
viru
spermin
spermidin
figur
anoth
bind
site
polyamin
protein
significantli
distinct
amantadin
bind
site
polyamin
attract
much
attent
develop
novel
antiinfluenza
drug
spiropiperidin
deriv
repres
compound
figur
also
effect
protein
show
activ
amantadineresist
virus
natur
product
pinanamin
deriv
compound
figur
also
exhibit
good
antiinfluenza
activ
howev
almost
none
inhibitor
effect
influenza
b
viru
mopyridon
figur
compound
screen
seri
pyrimidinon
deriv
galabov
et
al
demonstr
larg
scope
antiflu
effect
larg
spectrum
influenza
b
strain
vitro
vivo
particularli
noteworthi
compound
antiflu
compound
prove
target
protein
research
show
compound
low
acut
toxic
mice
develop
pharmaceut
chemistri
research
center
former
soviet
union
arbidol
hydrochlorid
ah
figur
select
new
antivir
drug
influenza
infect
russia
china
ah
effect
prophylaxi
treatment
influenza
acut
respiratori
viral
infect
arvi
ah
inhibit
viral
entri
target
cell
also
stimul
immun
respons
time
ah
immunomodulatori
activ
capac
induc
interferon
antioxid
properti
although
studi
russia
china
prove
ah
effect
approv
use
western
countri
interact
host
proteas
splice
site
viral
precursor
protein
determin
whether
speci
infect
influenza
affect
virul
viru
exampl
splice
site
highli
pathogen
avian
influenza
strain
easili
splice
widespread
basic
amino
acid
proteas
serin
proteas
result
fatal
system
infect
bird
fact
known
inhibitor
nafamostat
leupeptin
epsilonaminocapron
acid
camostat
aprotinin
studi
year
figur
camostat
shown
select
inhibit
influenza
influenza
b
virus
vitro
vivo
select
vatpas
inhibitor
may
increas
intern
ph
prelysosom
therebi
inhibit
conform
transform
ha
unfus
conform
fuse
conform
would
result
inhibit
replic
cours
viral
life
cycl
interest
four
drug
use
treatment
parkinson
diseas
norakinr
parkopanr
antiparkinr
akinetonr
contain
adamantin
scaffold
shown
inhibitori
activ
influenza
influenza
b
virus
increas
evid
indic
oxid
play
major
role
influenza
viru
life
cycl
replic
among
antivir
strategi
make
use
antioxid
alphatocopherol
figur
enjoy
long
histori
sinc
research
reveal
alphatocopherol
combin
could
normal
lipid
peroxid
process
caus
viral
infect
activ
nadph
oxidas
might
promot
respiratori
symptom
result
infect
influenza
virus
imped
clearanc
viru
therefor
nadph
oxidas
becam
promis
novel
pharmacolog
target
influenza
viru
infect
describ
research
develop
antiinfluenza
drug
ongo
decad
greatli
progress
howev
drug
resist
acquir
recent
year
widespread
use
antiinfluenza
drug
prompt
research
find
new
potenti
target
pathway
inhibitor
mtor
inhibitor
rapamycin
figur
market
immunosuppress
drug
surprisingli
lead
protect
infect
multipl
subtyp
influenza
viru
addit
proteasom
inhibitor
inhibitor
bortezomib
figur
rafmekerk
pathway
inhibitor
also
effect
work
new
antivir
influenza
viru
inhibitor
nonstructur
protein
influenza
viru
small
multifunct
protein
play
critic
role
respons
host
antivir
process
bind
cleavag
polyadenyl
specif
factor
matur
host
rna
block
lead
reduct
host
protein
twu
cowork
found
bind
mediat
second
third
zinc
finger
bind
process
protein
block
fragment
contain
bind
motif
replic
influenza
viru
inhibit
work
indic
bind
site
protein
potenti
target
antivir
therapi
influenza
viru
recent
studi
carri
jablonski
et
al
show
seri
compound
deriv
figur
compound
display
inhibitori
activ
protein
phospholipas
inhibitor
phospholipas
pld
one
kind
phospholipas
catalyz
format
phosphatid
acid
import
messeng
signal
metabol
pathway
recent
studi
show
human
inhibitor
figur
possess
broadspectrum
inhibitori
influenza
strain
vrnp
inhibitor
export
influenza
viru
vrnp
nuclear
demonstr
mediat
hostexportin
develop
inhibitor
interrupt
vrnp
export
process
hinder
replicationcycl
viru
make
sens
studi
perform
olivia
perwitasari
et
al
show
verdinexor
figur
novel
select
inhibitor
select
potent
inhibit
replic
process
variou
influenza
viru
b
strain
vitro
resveratrol
figur
could
interrupt
transloc
process
rnp
nucleu
cytoplasm
may
use
antiinfluenza
drug
ascorb
dehydroascorb
acid
figur
also
possess
antivir
effect
effect
may
work
envelop
viral
nucleocapsid
complet
viral
dna
replic
rna
inhibitor
rna
inhibitor
refer
molecul
regul
express
gene
rna
inhibitor
play
import
role
rna
silenc
rna
interfer
posttranscript
regul
gene
express
rna
inhibitor
abl
regul
express
influenza
viral
rna
accordingli
viral
gene
becam
potenti
target
rna
inhibitor
may
effect
influenza
treatment
immunomodulatori
agent
inflammatori
chang
immun
reaction
associ
acut
coronari
syndrom
may
influenc
mortal
influenza
immunomodulatori
agent
reduc
level
ldlcholesterol
improv
inflammatori
chang
studi
show
statin
treatment
pneumonia
patient
influenza
patient
exhibit
reduc
mortal
immunomodulatori
agent
cyclooxygenas
inhibitor
aspirin
ace
inhibitor
acei
angiotensin
receptor
blocker
arb
ampk
agonist
metformin
agonist
fibrat
glitazon
howev
showd
abil
reduc
mortal
mous
model
influenza
patient
pneumonia
arb
acei
combin
therapi
combin
therapi
one
prospect
domain
investig
antiflu
agent
combin
therapi
use
antiinfluenza
treatment
may
improv
clinic
outcom
enhanc
antivir
activ
drugresist
strain
also
reduc
risk
side
effect
doserel
toxic
mortal
morbid
therefor
combin
therapi
recommend
clinic
classifi
earli
combin
chemotherapi
sequenti
multidrug
chemotherapi
classic
combin
blocker
na
inhibitor
avoid
drugresist
mani
studi
carri
evalu
efficaci
combin
therapi
singledrug
treatment
combin
therapi
show
superior
outcom
mice
model
drug
resist
often
caus
monotherapi
sometim
uncontrol
use
farm
anim
frequent
mutat
strain
increasingli
seriou
past
year
drug
effect
situat
develop
antivir
agent
practic
signific
topic
attract
much
attent
made
great
progress
past
sever
decad
small
molecular
inhibitor
power
weapon
fight
influenza
viru
small
molecular
inhibitor
function
ionchannel
inhibitor
na
inhibitor
proteas
inhibitor
use
clinic
ionchannel
inhibitor
firstli
use
clinic
shown
defect
clinic
use
quick
develop
drugresist
strain
type
b
virus
limit
clinic
use
altern
na
inhibitor
current
popular
target
antivir
research
oseltamivir
zanamivir
effect
amantadan
resist
strain
arbidol
hydrochlorid
effect
influenza
b
virus
precis
mechan
action
remain
unclear
use
market
na
inhibitor
oseltamivir
zanamivir
also
limit
due
increas
preval
resist
strain
besid
monotherapi
combin
therapi
also
develop
treatment
immunomodulatori
agent
also
repres
new
approach
deal
season
pandem
influenza
along
determin
na
structur
discoveri
sar
recent
year
basi
ration
design
novel
potent
nai
valid
drug
resist
becam
increasingli
seriou
problem
exist
drug
may
longer
use
due
emerg
mutat
strain
research
focus
make
structur
modif
current
drug
identifi
potenti
new
target
ha
ha
inhibitor
rnadepend
rna
polymeras
rdrp
inhibitor
nucleocapsid
protein
np
inhibitor
proteas
inhibitor
vatpas
inhibitor
pathway
inhibitor
antioxid
phospholipas
inhibitor
vrnp
inhibitor
rna
inhibitor
etc
inhibitor
target
shown
certain
antiinfluenza
activ
vivo
vitro
studi
progress
particularli
worth
mention
major
progress
made
unravel
function
mechan
viru
polymeras
past
year
well
novel
rdrp
inhibitor
anticip
polymeras
inhibitor
reshap
field
influenza
prevent
therapi
near
futur
howev
still
long
way
go
win
battl
influenza
pandem
